North America Kidney Disease Market Dynamics and Trends by 2027

The North America kidney disease market is expected to reach US$ 42,462.1 million in 2027 from US$ 25,483.5million in 2019. The market is estimated to grow with a CAGR of 6.7% from 2020-2027.

Kidney disease is also known as renal disease. It is caused due to the malfunctioning of the kidney. There are various types of kidney diseases including kidney stones, glomerulonephritis, urinary tract infections, and others. For the treatment and diagnosis of these types of diseases, different global and regional players are offering various products and services. The scope of the kidney disease market includes product, end-user, and region.

US Kidney Disease Market Revenue and Forecasts to 2027 (US$ MN)

Market Insights

A High Rise in Research & Development Regarding Kidney Diseases

The government is spending more on the healthcare sector and its related programs. Research and development are at a high rise in the market. Chronic Kidney Disease care in Mexico is unequal, unjust, and below the quality of global standards. At present, the resources and infrastructure are insufficient to satisfy the demand for renal care in Mexico. Therefore, the government is focusing on the consolidation of renal care in order to improve treatment outcomes as well as patient experience. For instance, the implementation of community screening programs for kidney disease diagnosis and establishing the National ESRD registry generates lucrative market opportunities during the forecast years. The growing investments in the development of new therapies in Canada are likely to show a positive impact on the growth of the market. For instance, in May 2016, the group of researchers at the University of British Columbia initiated a program to improve the care of patients suffering from chronic kidney disease. Moreover, the Canadian government invested around US$ 59.0 million to catalyze research and development at the university.Therefore, a high rise in research and development is likely to generate lucrative opportunities for the growth of the kidney disease market.

Product- Based Market Insights

Based on product,thekidney disease marketis segmented into diagnosis and treatment. The diagnosis segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

North America Kidney Disease Market, by Product – 2019 and 2027

End-User - Based Market Insights

Based on end-user, the kidney disease market, is segmented into hospitals, diagnostic laboratories, and others. The hospitals segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

North America Kidney Disease Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the kidney disease market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance,in August 2020, Tricida, Inc. received FDA approval for its veverimer (TRC101), an orally-administered polymer for treating metabolic acidosis in patients with chronic kidney disease (CKD).

NORTH AMERICA KIDNEY DISEASE MARKET SEGMENTATION

By Product

• Diagnosis

o      Blood Tests

o      Urine Tests

o      Imaging Tests

o      Others

• Treatment

o      Dialysis

o      Others

o      Drug Class

• • • ACE Inhibitors
    • Angiotensin-II Receptor Blockers
    • Diuretics
    • Others

By End User

• Hospitals
• Diagnostic Laboratories
• Others

By Country

• US
• Canada
• Mexico

Company Profiles

• Abbott
• F. Hoffmann-La Roche Ltd
• AbbVieInc
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc
• Amgen Inc
• Sysmex Corporation
• Siemens AG

North America Kidney Disease Market Report Scope

North America Kidney Disease Market Players Density: Understanding Its Impact on Business Dynamics

The North America Kidney Disease Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.